Ronald Blue Trust, Inc. Arcus Biosciences, Inc. Transaction History
Ronald Blue Trust, Inc.
- $8.16 Billion
- Q4 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 382 shares of RCUS stock, worth $5,027. This represents 0.0% of its overall portfolio holdings.
Number of Shares
382
Previous 376
1.6%
Holding current value
$5,027
Previous $5,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding RCUS
# of Institutions
200Shares Held
51.5MCall Options Held
236KPut Options Held
141K-
Black Rock Inc. New York, NY9.76MShares$128 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$72 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$45.8 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$39.6 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.44MShares$32.1 Million0.1% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $950M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...